Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLG versus ATG for immune reconstitution after allo-HSCT in malignant hematologic diseases
ChiCTR2500095404Phase 4Not yet recruiting
- Sponsor
- Department of Hematology, Peking University First Hospital
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of antithymocyte globulin rabbit in hematopoietic malignancies (2 arms), sponsored by Department of Hematology, Peking University First Hospital. Primary endpoints: Cytomegalovirus (CMV) reactivation, Cytomegalovirus (CMV) disease and 2 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on ChiCTR2500095404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095404.